Detalhe da pesquisa
1.
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.
Blood
; 141(6): 579-591, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36130300
2.
T-cell-engaging bispecific antibodies in cancer.
Lancet
; 402(10396): 142-158, 2023 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37271153
3.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269857
4.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Lancet Oncol
; 24(10): 1119-1133, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37717583
5.
T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
Curr Opin Oncol
; 35(6): 601-611, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37501530
6.
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
Br J Haematol
; 198(2): 317-327, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35476316
7.
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
Haematologica
; 107(2): 437-445, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33375774
8.
Sexual problems in patients with hematological diseases: a systematic literature review.
Support Care Cancer
; 30(6): 4603-4616, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35061099
9.
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.
Lancet Oncol
; 22(3): e119-e130, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33545067
10.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931
11.
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Br J Haematol
; 194(3): 496-507, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33724461
12.
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Haematologica
; 106(11): 2799-2812, 2021 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34261295
13.
Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
Clin Chem Lab Med
; 59(12): 1963-1971, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34392637
14.
Management of patients with difficult-to-treat multiple myeloma.
Future Oncol
; 17(16): 2089-2105, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33706558
15.
Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials.
Support Care Cancer
; 29(7): 3783-3792, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33236210
16.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet
; 393(10168): 253-264, 2019 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30545780
17.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet
; 394(10192): 29-38, 2019 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171419
18.
Equality: trial and error?
Blood
; 142(3): 212-214, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37471108
19.
Maintain maintenance in multiple myeloma?
Blood
; 142(18): 1501-1502, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37917081
20.
RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML.
Blood
; 131(22): 2485-2489, 2018 05 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29669779